Are you Dr. Brachmann?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 13 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
Uci Medical Center
101 The City Drive South
Orange, CA 92868Phone+1 714-456-8978
Summary
- Dr. Rainer Brachmann, MD is an oncologist in Orange, California.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1993 - 1996
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1990 - 1993
Ludwig Maximilian University of Munich Faculty of MedicineClass of 1987
Clinical Trials
- A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2008 Sep 01
- A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2009 Aug 01
- A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2015 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 75 citationsPhase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancerJennifer R. Diamond, Carlos Becerra, Donald A. Richards, Alain C. Mita, Cynthia Osborne
Breast Cancer Research and Treatment. 2020-08-14 - 36 citationsPhase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic CancerEfrat Dotan, Dana Backlund Cardin, Heinz-Josef Lenz, Wells A. Messersmith, Bert H. O'Neil
Clinical Cancer Research. 2020-07-21 - 68 citationsA phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.Kathleen N. Moore, Camille C. Gunderson, Paul Sabbatini, D. Scott McMeekin, Gina Mantia-Smaldone
Gynecologic Oncology. 2019-08-01
